AbbVie

ABBV

Market cap $402B

The stocks listed below yield between 2.7% and 3.5%. They are in different sectors of the economy and can help diversify your portfolio while also generating plenty of recurring cash flow.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is slightly below 2024 levels.

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).

Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.

ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster innovation and support growth in Quebec's life sciences sector.

NORTH CHICAGO, Ill. , Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.

These dividend stocks represent the communications services, energy, financial services, healthcare, and real estate sectors. All of them have attractive dividend yields.

JPM shows solid operational strength as analysts highlight its NII outlook, fee pressures and expense trajectory through 2027.

Trying to build a portfolio that can survive recessions, inflation, and market volatility is one of the biggest challenges any investor can face.